AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
AI-Derived AlloView Results Correlate with Presence and Type of Biopsy Proven Kidney Rejection
Longitudinal Monitoring with AlloSure Kidney Enables Earlier Identification of Graft Injury and Assessment of Rejection Treatment
KOAR Data Show Kidney Biopsies Informed by AlloSure Detect More Acute Rejection than Biopsies Based on Traditional Indications
“The additive value of artificial intelligence to our transplant solutions holds significant promise,” said
Key data to be presented at 2024 ATC:
-
Utilization of Artificial Intelligence (AI) in Predicting the Risk of Kidney Allograft Rejection,
S. V. Shah ,S. Voora ,P. J. Hanson , et al. Poster Abstract Session D148. This independent study establishes reference values for AlloView™, correlating results with the presence and type of allograft rejection observed on kidney biopsies. AlloView is the first AI-derived model to predict rejection risk in kidney transplant patients by integrating AlloSure Kidney with other clinical and laboratory factors associated with rejection. -
Time-Varying Relative Changes in Donor-Derived Cell-Free DNA (dd-cfDNA) during Rejection and dnDSA Detection in Primary and Repeat Kidney Transplant Recipients (KTR),
S. Parajuli ,N. Garg ,K. Pinney , et al. Poster Abstract Session A184. This study highlights the importance of AlloSure® Kidney for longitudinal monitoring of dd-cfDNA trends, enabling earlier identification of evolving graft injury and evaluating rejection treatment response. -
Donor-Derived Cell-Free DNA Increases the Yield of Acute Rejection and Borderline TCMR on Kidney Transplant Biopsies,
J. Bromberg ,D. Mandelbrot ,M. Weir , et al. Poster Abstract Session A174. An analysis of KOAR (Kidney Outcomes with AlloSure Registry) data show that kidney biopsies based on AlloSure alone or AlloSure and traditional laboratory indications, significantly enhance detection of actionable findings, yielding acute rejection and borderline T-cell mediated rejection (TCMR) in 48% of cases compared to 28% with traditional for-cause biopsy indications alone. -
Clinical Utility of Donor-Derived Cell-Free DNA during the Period of Recovery of Renal Function after Kidney Transplantation,
R. D. Foresto , Y. C. Dreige, I. Meira, et al, Rapid Fire Oral Abstract Session 363. Data show that using a threshold of AlloSure Kidney dd-cfDNA of >0.5% to guide surveillance biopsies during delayed graft function (DGF) or at 30 days post-transplant in the setting of incomplete recovery of kidney function would have avoided 23% and 36% of biopsies, respectively. -
Characterization of GEP and dd-cfDNA Profile with Long-Term Malignancy Risk Post-Cardiac Transplant,
L. Chen ,D. H. Lee ,E. Czinn , et al. Poster Abstract Session C062. The study reveals that patients developing cancer after heart transplantation have lower mean levels of both AlloMap® gene-expression profiling and AlloSure dd-cfDNA before cancer diagnosis compared to propensity-matched patients.
A leading group of experts in the field will present findings from the recent SHORE (Surveillance HeartCare Outcomes Registry) publication and the latest data featuring AlloSure Kidney and AlloView, the first AI-derived model to predict rejection risk in kidney transplant patients. The sponsored symposium1, “From Invasive to Intelligent: Utilizing Cutting-Edge Artificial Intelligence and
"I am thrilled to moderate this exciting symposium sponsored by
For a complete listing of abstracts, oral presentations and posters go here.
About
Forward Looking Statements
This press release includes forward-looking statements related to
References:
- The symposium is an independent, non-CME event.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530179664/en/
Media Relations
818-731-2203
aczene@caredx.com
Investor Relations
investor@caredx.com
Source: